Use of Sodium Channel Blockers in the Thr226Met Pathologic Variant of SCN1A: A Case Report
Authors:
Open Access
- 19 July 2023
- journal article
- research article
- Published by Georg Thieme Verlag KG in Neuropediatrics
- Vol. 54 (06) , 417-421
Abstract
The Thr226Met pathologic variant of the SCN1A gene has been associated with the clinical development of an early infantile developmental and epileptic encephalopathy (EIDEE) different from Dravet's syndrome. The electrophysiological mechanisms of the mutated channel lead to a paradoxical gain and loss of function. The use of sodium channel blockers (SCB) that counteract this gain of function has been described in previous studies and they can be safely administered to patients carrying mutations in other sodium channel subtypes without causing a worsening of seizures. We report the use of SCB in a child harboring the Thr226Met pathologic variant of SCN1A with early-onset pharmaco-resistant migrating seizures, as well as developmental delay. Lacosamide led to a dramatic reduction in seizure frequency; however, only a mild improvement in the epileptic activity depicted by electroencephalography (EEG) was achieved. The introduction of carbamazepine as an add-on therapy led to a notable reduction in epileptic activity via EEG and to an improvement in sensorimotor development. Despite the overall clinical improvement, the patient developed febrile seizures and a nonepileptic jerking of the right hand. In this case of EIDEE with the Thr226Met variant, we demonstrate a beneficial pharmacological intervention of SCB in contrast to findings described in current literature. Our report encourages the cautious use of SCB at early stages of the disease in patients carrying this pathologic variant.Keywords
This publication has 14 references indexed in Scilit:
- SCN1A gain of function in early infantile encephalopathyAnnals of Neurology, 2019
- Not all SCN1A epileptic encephalopathies are Dravet syndromeNeurology, 2017
- Temperature-dependent changes in neuronal dynamics in a patient with an SCN1A mutation and hyperthermia induced seizuresScientific Reports, 2016
- TheSCN1AMutation Database: Updating Information and Analysis of the Relationships among Genotype, Functional Alteration, and PhenotypeHuman Mutation, 2015
- Current understanding of the mechanism of action of the antiepileptic drug lacosamideEpilepsy Research, 2015
- Febrile temperatures unmask biophysical defects in Nav1.1 epilepsy mutations supportive of seizure initiationJournal of General Physiology, 2013
- The developmental changes of Nav1.1 and Nav1.2 expression in the human hippocampus and temporal lobeBrain Research, 2011
- Partial epilepsy with antecedent febrile seizures and seizure aggravation by antiepileptic drugs: Associated with loss of function of Nav1.1Epilepsia, 2010
- Nav1.1 Localizes to Axons of Parvalbumin-Positive Inhibitory Interneurons: A Circuit Basis for Epileptic Seizures in Mice Carrying anScn1aGene MutationThe Journal of Neuroscience, 2007
- Depolarization Block of Neurons During Maintenance of Electrographic SeizuresJournal of Neurophysiology, 2003